GlassScriptPhysician profile
Ira Freilich
NPI 1427081496
$9,566.15
in general payments reported to CMS, 2019-2025
30 companies · $1,409 in 2025
The $1,409 reported for 2025 was more than what 82% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $346 · 2020: $629 · 2021: $1,088 · 2022: $1,335 · 2023: $2,147 · 2024: $2,612 · 2025: $1,409.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,095 · Education: $72.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,095.46 |
| Education | $72.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $1,131.31 | 2021-2025 | Opzelura, Opzelura |
| Abbvie INC. | $1,086.85 | 2020-2025 | |
| Pfizer INC. | $960.63 | 2020-2025 | |
| Ucb, INC. | $854.62 | 2020-2025 | Bimzelx, Cimzia |
| Genzyme Corporation | $816.92 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $662.05 | 2020-2025 | Dupixent, Libtayo |
| Leo Pharma INC. | $533.37 | 2021-2025 | Adbry |
| Novartis Pharmaceuticals Corporation | $437.41 | 2019-2024 | |
| Sun Pharmaceutical Industries INC. | $416.35 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $378.64 | 2022-2025 | Sotyktu |
| Lilly USA, LLC | $347.43 | 2020-2025 | Taltz, Ebglyss |
| Janssen Biotech, INC. | $302.29 | 2021-2025 | Tremfya, Simponi Aria, Simponi |
| Amgen INC. | $216.92 | 2020-2025 | Otezla |
| Galderma Laboratories, L.P. | $195.01 | 2020-2025 | Nemluvio |
| Janssen Scientific Affairs, LLC | $185.32 | 2019-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Convatec INC. | $151.28 | 2023 | |
| Vyne Pharmaceuticals INC. | $145.54 | 2020 | |
| Arcutis Biotherapeutics, INC. | $140.62 | 2024-2025 | Zoryve |
| Misonix INC | $111.66 | 2021 | |
| Merck Sharp & Dohme LLC | $109.02 | 2019 | |
| Novo Nordisk INC | $103.60 | 2023 | |
| Heartflow, INC. | $86.24 | 2022 | |
| Genentech, INC. | $50.00 | 2023 | Xolair |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.99 | 2025 | Spevigo |
| Almirall LLC | $24.26 | 2023 | Klisyri |
| Teva Pharmaceuticals USA, INC. | $24.18 | 2024 | Simlandi |
| Biofrontera INC. | $21.25 | 2025 | Ameluz |
| Celgene Corporation | $18.62 | 2019 | |
| Verrica Pharmaceuticals INC. | $16.51 | 2024 | Ycanth |
| Strata Skin Sciences, INC. | $12.26 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ira Freilich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.